Novartis is conducting a study on "a primary myelofibrosis (PMF), red blood cell characteristics in secondary myelofibrosis increased (PPV-M
Novartis is conducting a study on "a primary myelofibrosis (PMF), red blood cell characteristics in secondary myelofibrosis increased (PPV-MF) or essential thrombocythemia with bone marrow fibrosis (PET-MF) and the baseline platelet count greater than 50 x109/L and < INC424 tablets in patients (100 x109/L JAK inhibitor, brand name Lu ruxolitinib, formerly known as Ruxolitinib) English oral research openness, dose determination and Ib medicine". The study was not listed in china. The trial will enroll approximately 72 patients worldwide. Screening of qualified patients, will be able to get a free test drug treatment and the provisions of the program. Recruitment of eligible patients with myelofibrosis
If you or you are surrounded by patients who meet the following conditions, and can be in accordance with the requirements of the doctor for examination, treatment and follow-up. You can contact our doctor:
- confirmed PMF, PPV-MF or PET-MF in male or female patients, and according to the International Working Group (IMG) of the definition, belong to high-risk (with 3 or more than 3 kinds of prognostic factors or risk (-2) with 2 kinds of prognostic factors in -1 (1) or dangerous for prognosis factors) (Cervantes et al. 2009);
Can reach splenomegaly, ratio of rib lower than 5cm, and has active symptoms;
For the first layer of PLT, X and 109/L count < 100 x 109/L = 75, for the second layer of the quota is full.
Contact: Duan Minghui
The Department of Hematology of Peking Union Medical College Hospital (East Hospital, every Monday, three morning, afternoon four general out-patient, Thursday morning special outpatient service)